Drug Details
| General Information of the Drug (ID: DR8551) | ||||
|---|---|---|---|---|
| Name |
Decitabine
|
|||
| Synonyms |
AzadC; Dacogen; Dezocitidine; NCGC_5ADOC; Dacogen (TN); E-7373; Decitabine (USAN/INN); Dacogen, 5-aza-2'-deoxycytidine,NSC 127716, Dacogen, DAC, Decitabine; 2'-Deoxy-5-azacytidine; 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one; 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-s-triazin-2(1H)-one; 4-Amino-1-(2-deoxy-beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; 4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one; 5-AZAdC; 5-Aza-2′ 5-Azadeoxycytidine; 5-Deoxy-2′ 5-aza-2-deoxycytidine; 5-aza-CdR; 5-aza-dC; 5A2dc
Click to Show/Hide
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Myelodysplastic syndrome [ICD-11: 2A37] | Approved | [1] | |
| Structure |
|
Click to Download Mol2D MOL |
||
| ADMET Property |
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 1332 mcgh/L
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 73.8 mcg/L
Clearance
The drug present in the plasma can be removed from the body at the rate of 130 mL/min/kg
Elimination
Less than 1% of administered decitabine is excreted in the urine
Half-life
The concentration or amount of drug in body reduced by one-half in 0.62 hours
Metabolism
The drug is metabolized via the sequential action of deoxycytidine kinase, nucleotide monophosphate kinase, and nucleotide diphosphate kinase
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 4.8733 micromolar/kg/day
Unbound Fraction
The unbound fraction of drug in plasma is 1%
Vd
The volume of distribution (Vd) of drug is 4.59 +/- 1.42 L/kg
Click to Show/Hide
|
|||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| Formula |
C8H12N4O4
|
|||
| PubChem CID | ||||
| Canonical SMILES |
C1C(C(OC1N2C=NC(=NC2=O)N)CO)O
|
|||
| InChI |
1S/C8H12N4O4/c9-7-10-3-12(8(15)11-7)6-1-4(14)5(2-13)16-6/h3-6,13-14H,1-2H2,(H2,9,11,15)/t4-,5+,6+/m0/s1
|
|||
| InChIKey |
XAUDJQYHKZQPEU-KVQBGUIXSA-N
|
|||
| CAS Number |
CAS 2353-33-5
|
|||
| ChEBI ID | ||||
| TTD Drug ID | ||||
| DrugBank ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Arsenic trioxide | Realgar and orpiment | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| In-vitro Model | MV4-11 | CVCL_0064 | Childhood acute monocytic leukemia | Homo sapiens | ||
| Experimental
Result(s) |
Effect of decitabine in combination with arsenic trioxide on prolife-ration and apoptosis of human acute myeloid leukemia MV4-11 cells. | |||||
| Genistein | Glycine max | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| In-vitro Model | HL-60 | CVCL_0002 | Adult acute myeloid leukemia | Homo sapiens | ||
| MOLT-3 | CVCL_0624 | Adult T acute lymphoblastic leukemia | Homo sapiens | |||
| L1210 | CVCL_0382 | Mouse leukemia | Mus musculus | |||
| In-vivo Model | Male CD2F1 mice (24-28 g) were injested with L1210 leukemic cells intravenously into the lateral tail vein. | |||||
| Experimental
Result(s) |
The combined treatment produced a synergistic loss of clonogenicity in human myeloid (HL-60) and lymphoid (MOLT-3) leukemic cell lines. | |||||
| Paclitaxel | Taxus brevifolia | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [4] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | TGFB1 | Molecule Info | ||
| In-vitro Model | ACHN | CVCL_1067 | Papillary renal cell carcinoma | Homo sapiens | ||
| Caki-1 | CVCL_0234 | Clear cell renal cell carcinoma | Homo sapiens | |||
| Caki-2 | CVCL_0235 | Renal cell carcinoma | Homo sapiens | |||
| NC 65 | Renal cell carcinoma | Homo sapiens | ||||
| In-vivo Model | 1*107 ACHN or Caki-1 cells were injected into the backs of each mouse. | |||||
| Experimental
Result(s) |
Paclitaxel in combination with 5-aza-2'-deoxycytidine enhances susceptibility of renal cell carcinoma through VHL-TGFBI signaling. | |||||
| Sulforaphane | Brassica oleracea | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [5] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| In-vitro Model | B16-F10 | CVCL_0159 | Mouse melanoma | Mus musculus | ||
| Experimental
Result(s) |
combinational treatments with SFN and DAC results in melanoma cell growth inhibition and specific changes in gene expression profiles. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Human Deoxyribonucleic acid (hDNA) | Molecule Info | [6] | |
